What type of study is this?

Efficacy of neoadjuvant chemoimmunotherapy in locally advanced resectable esophageal cancer

View Full Paper

Ask AI

Bookmark

Neoadjuvant chemoimmunotherapy significantly improved pathological response rates and patient survival.
The study included 379 patients and reported a pathological complete response rate of 27.2%.
Pathological responses were evaluated using Kaplan–Meier methods with multivariate Cox regression analysis.
The findings suggest NICT could transform treatment strategies while maintaining an acceptable safety profile.

No takes yet. Share an insight, caveat, or question.

Retrospective analysis shows neoadjuvant chemoimmunotherapy enhances survival rates in esophageal cancer, indicating effective treatment strategies.

Yi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis shows neoadjuvant chemoimmunotherapy enhances survival rates in esophageal cancer, indicating effective treatment strategies.